{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:05:04Z","timestamp":1770822304602,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1053\/j.seminhematol.2004.02.006","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T13:00:54Z","timestamp":1086786054000},"page":"15-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S3","title":["The leukemia controversy in myeloproliferative disorders: Is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?"],"prefix":"10.1053","volume":"41","author":[{"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2004.02.006_BIB1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.1998.01021.x","article-title":"No treatment for low risk thrombocythemia","volume":"103","author":"Ruggeri","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.006_BIB2","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.006_BIB3","first-page":"17","article-title":"From efficacy to safety","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.006_BIB4","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera","volume":"90","author":"Najean","year":"1977","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.006_BIB5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.7326\/0003-4819-119-11-199312010-00006","article-title":"Interferon-\u03b12b","volume":"119","author":"Silver","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2004.02.006_BIB6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","article-title":"Interferon-\u03b1 in the treatment of polycythemia vera","volume":"79","author":"Lengfelder","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.006_BIB7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythemia","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.006_BIB8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.006_BIB9","first-page":"70a","article-title":"Anagrelide","volume":"100","author":"Fruchtman","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.006_BIB10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196304000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196304000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:12:15Z","timestamp":1758521535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196304000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":10,"alternative-id":["S0037196304000344"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2004.02.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The leukemia controversy in myeloproliferative disorders: Is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2004.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}